

Editorial

## 2016 Eberhard F. Mammen Award Announcements: Part I — Most Popular Articles

Emmanuel J. Favaloro, PhD, FFSc (RCPA)<sup>1</sup>

<sup>1</sup>Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, NSW, Australia

Semin Thromb Hemost 2016;42:325–330.

Welcome to the latest of our Eberhard F. Mammen award announcements. As noted previously,<sup>1–3</sup> Thieme, the publisher of *Seminars in Thrombosis & Hemostasis*, has created the *Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards* in honor of Eberhard Mammen (► **Fig. 1**) and in recognition of his contribution to this field and to the journal that he both founded and steered for over three decades. These awards began in 2009, under two categories, “Most Popular Article Awards” and “Young Investigator Awards.” Current details and conditions of the award can be summarized as:

- **Most Popular Article Awards:** The awards are given to the authors of the most popular articles published in *Seminars in Thrombosis & Hemostasis*. The awards are determined by the Editor in Chief on the basis of user statistics from Thieme e-Journals from the preceding 2 years. Prefaces, Errata, Letters



**Fig. 1** Eberhard F. Mammen (1930–2008).

to the Editor, Editorials, and previous award-winning articles are excluded from further consideration of these awards, which currently comprise two categories—one for “Open Access” articles, and another for a “General Category.” There are two major cash prizes of US\$1,000 for each category. In addition, winners of the “General Category” awards are granted “open-access” status for these articles thereafter.

- **Young Investigator Awards:** These award are given for best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr. Mammen. There are up to six cash prizes of US\$1,000 in any year. There are some additional considerations and conditions for the award, and awardees are expected to prepare a review or other paper related to the topic of their presentation for publication in *Seminars in Thrombosis & Hemostasis*.

Further details of the awards and the award winners are posted online (<http://www.thieme.com/sth>), and previous award winner announcements are also available in print.<sup>4–13</sup>

It is therefore with great pleasure that we would like to announce the latest winners of the 2016 Eberhard F. Mammen awards for the most popular articles from *Seminars in Thrombosis & Hemostasis* for the period of 2014–2015 inclusive. We will be announcing the Young Investigator Awards related to meetings held in the recent past at a forthcoming opportunity.

### 2016 “Most Popular Article” Awards

As mentioned, the Most Popular awards are given to the authors of the most popular articles published in *Seminars in Thrombosis & Hemostasis* as determined on the basis of user statistics from

**Address for correspondence**  
Emmanuel J. Favaloro, PhD, FFSc (RCPA), Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, NSW, 2145, Australia (e-mail: emmanuel.favaloro@health.nsw.gov.au).

**Issue Theme** The Role of Fibrinogen and Factor XIII in Hemostasis, and the Identification and Treatment of Associated Disorders; Guest Editors: Ton Lisman, PhD, and Philippe de Moerloose, MD.

Copyright © 2016 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.  
Tel: +1(212) 584-4662.

DOI <http://dx.doi.org/10.1055/s-0036-1581108>.  
ISSN 0094-6176.

the publisher of this journal and covering the preceding 2-year period. Thus, the 2016 “Most Popular” awards are granted to the most popular papers from 2014–2015 inclusive. Previous Eberhard F. Mammen award-winning articles are listed in ► **Table 1**. These articles are currently available under an “Open Access” status, and no longer qualify for future awards, although many will continue to appear in the most popular download statistics provided by the publisher.

There is also an increasingly recognized trend to publish articles in an open-access mode, and these have an “inequitable advantage” over other “non-open-access” articles in terms of downloads due to their open accessibility. Accordingly, the publisher of *Seminars in Thrombosis & Hemostasis* has established a separate category of the Most Popular Award for “open-access” papers, to supplement the alternate “General Category,” and thus the most popular papers are now listed in separate tables. ► **Table 2** lists the top 15 downloaded open-access articles from *Seminars in Thrombosis & Hemostasis* (2014 and 2015 inclusive) eligible for the “Open Access” award.<sup>14–28</sup> ► **Table 3** lists the top 15

downloaded non-open-access articles from *Seminars in Thrombosis & Hemostasis* (2014 and 2015 inclusive) eligible for the “General Category” award.<sup>29–43</sup>

Accordingly, the 2016 Eberhard F. Mammen award winners for Most Popular Articles (2014–2015 inclusive) are as follows:

#### Open Access Category

1. Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. *Semin Thromb Hemost* 2012;38(7):673–682
2. Lippi G, Favaloro EJ, Meschi T, Mattiuzzi C, Borghi L, Cervellin G. E-cigarettes and cardiovascular risk: beyond science and mysticism. *Semin Thromb Hemost* 2014;40(1):60–65

#### General Category

1. de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. *Semin Thromb Hemost* 2013;39(6):585–595

**Table 1** Previous most popular award winning papers

Year	Awarded for
2009	Jurk K, Kehrel BE. Platelets: physiology and biochemistry. <i>Semin Thromb Hemost</i> 2005;31(4):381–392
2009	Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. <i>Semin Thromb Hemost</i> 2006;32(8):803–809
2010	Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. <i>Semin Thromb Hemost</i> 2008;34(1):39–57
2010	Prechel M, Walenga JM. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. <i>Semin Thromb Hemost</i> 2008;34(1):86–96
2010	Fareed J, Hoppensteadt DA, Fareed D, et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. <i>Semin Thromb Hemost</i> 2008;34(1):58–73
2011	Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. <i>Semin Thromb Hemost</i> 2009;35(5):515–524
2011	Mariani G, Bernardi F. Factor VII deficiency. <i>Semin Thromb Hemost</i> 2009;35(4):400–406
2012	Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox.” <i>Semin Thromb Hemost</i> 2010;36(1):59–70
2012	Rak J. Microparticles in cancer. <i>Semin Thromb Hemost</i> 2010;36(8):888–906
2013	Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. <i>Semin Thromb Hemost</i> 2011;37(3):280–297
2013	Tufano A, Guida A, Dario Di Minno MN, Prisco D, Cerbone AM, Minno GD. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. <i>Semin Thromb Hemost</i> 2011 Apr;37(3):267–274
2014	Salmela B, Joutsu-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. <i>Semin Thromb Hemost</i> 2012;38(1):23–30
2014	Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. <i>Semin Thromb Hemost</i> 2012;38(1):47–54
2014	Kenet G, Aronis S, Berkun Y, et al. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. <i>Semin Thromb Hemost</i> 2011;37(7):802–809
2015	Tapson VF. Thrombolytic therapy for acute pulmonary embolism. <i>Semin Thromb Hemost</i> 2013;39(4):452–458
2015	George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. <i>Semin Thromb Hemost</i> 2013;39(2):153–160
2015 <sup>a</sup>	Hylek EM. Anticoagulation therapy for atrial fibrillation. <i>Semin Thromb Hemost</i> 2013;39(2):147–152
2015 <sup>a</sup>	Rojas-Hernandez CM, Garcia DA. The novel oral anticoagulants. <i>Semin Thromb Hemost</i> 2013;39(2):117–126

<sup>a</sup>New open-access category.

2. Sethi S, Fervenza FC. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS). *Semin Thromb Hemost* 2014;40(4):416–421

Although I was a co-author of one of the “Most Popular” award-winning papers, my contribution to this piece was limited. Moreover, I will excuse myself from any personal receipt of any aspect of the award. Accordingly, I do not consider there to be any conflict of interest in the publisher of *Seminars in Thrombosis & Hemostasis* awarding the award to the lead author, Prof. Giuseppe Lippi.

All authors of the award-winning articles were thrilled to hear that their papers had won an Eberhard F. Mammen Most Popular award, and provided the following additional responses:

From Dr. Shannon Bates (►Fig. 2), “I was surprised and very pleased to hear that my article had been awarded one of 2016 Most Popular Article Awards. Although I enjoy the opportunity that writing a review article provides to thoughtfully examine and synthesize the available literature, I must admit that I often wonder whether the resulting manuscript is of benefit to readers or even noticed. I am delighted, therefore, to find out that readers have found my article useful. It is an honor to receive this award.”

From Dr. Giuseppe Lippi (►Fig. 3), “I was really delighted to know that our article on ‘e-cigarettes and cardiovascular risk’ had won one of the Eberhard Mammen Seminars in Thrombosis & Hemostasis 2015 most popular article awards. The issues of the possible health hazard posed by E-cigarettes is as relevant now as ever, if one considers that approximately two thirds of national governments around the globe have established strict regulations for e-cigarettes as of 2015. Briefly, in 2014 the European Union established new regulations forbidding advertising, setting limits on maximum concentrations of nicotine, limiting volumes of liquid that can be sold, requiring child-proof and tamper-proof packaging and empowering regulators to take act should the regulations be violated. In April 2014 in Australia, a court decision has made it illegal to sell or supply electronic cigarettes in Western Australia, regardless of their appearance or nicotine content. In the US, with a lack of federal regulations, many states use local e-cigarette regulations, most commonly to prohibit sales to minors. It is also noteworthy that the US Food and Drug Administration (FDA) agency has recently established an on-line database (i.e., Adverse Event Reports for e-Cigarettes), aiming to collect voluntary reports of adverse events involving e-cigarettes from consumers, health professionals and members of the public. Health concerns were mostly related to the evidence of enhanced risk of cardiac

**Table 2** Most popular papers—“Open Access” category

Rank	Publication
1	Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. <i>Semin Thromb Hemost</i> 2012;38(7):673–682
2	Lippi G, Favaloro EJ, Meschi T, Mattiuzzi C, Borghi L, Cervellin G. E-cigarettes and cardiovascular risk: beyond science and mysticism. <i>Semin Thromb Hemost</i> 2014;40(1):60–65
3	Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. <i>Semin Thromb Hemost</i> 2014;40(2):163–171
4	Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach. <i>Semin Thromb Hemost</i> 2014;40(1):106–114
5	Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated thrombosis. <i>Semin Thromb Hemost</i> 2014;40(3):277–283
6	Raskob GE, Angchaisuksiri P, Blanco AN, et al.; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. <i>Semin Thromb Hemost</i> 2014;40(7):724–735
7	Favaloro EJ. Clinical utility of the PFA-100. <i>Semin Thromb Hemost</i> 2008;34(8):709–733
8	Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. <i>Semin Thromb Hemost</i> 2015;41(1):49–60
9	Zolfaghari S, Harenberg J, Froelich L, Wehling M, Weiss C. Development of a tool to identify patients’ preference for vitamin k antagonist or direct oral anticoagulant therapy. <i>Semin Thromb Hemost</i> 2014;40(1):121–128
10	Althaus K, Greinacher A. MYH9-related platelet disorders. <i>Semin Thromb Hemost</i> 2009;35(2):189–203
11	Nurden AT. Platelet membrane glycoproteins: a historical review. <i>Semin Thromb Hemost</i> 2014;40(5):577–584
12	Harenberg J, Kraemer S, Du S, et al. Determination of direct oral anticoagulants from human serum samples. <i>Semin Thromb Hemost</i> 2014;40(1):129–134
13	Favaloro EJ, Lippi G. Laboratory testing in the era of direct or non-vitamin k antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors. <i>Semin Thromb Hemost</i> 2015;41(2):208–227
14	Wada H, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. <i>Semin Thromb Hemost</i> 2008;34(8):772–778
15	Harenberg J, Du S, Krämer S, Weiss C, Krämer R, Wehling M. Patients’ serum and urine as easily accessible samples for the measurement of non-vitamin k antagonist oral anticoagulants. <i>Semin Thromb Hemost</i> 2015;41(2):228–236

**Table 3** Most popular papers—"General Category"

Rank	Publication
1	de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. <i>Semin Thromb Hemost</i> 2013;39(6):585–595
2	Sethi S, Fervenza FC. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS). <i>Semin Thromb Hemost</i> 2014;40(4):416–421
3	Riedl M, Fakhouri F, Le Quintrec M, et al. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. <i>Semin Thromb Hemost</i> 2014;40(4):444–464
4	Duga S, Salomon O. Congenital factor XI deficiency: an update. <i>Semin Thromb Hemost</i> 2013;39(6):621–631
5	Vivarelli M, Emma F. Treatment of C3 glomerulopathy with complement blockers. <i>Semin Thromb Hemost</i> 2014;40(4):472–477
6	Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. <i>Semin Thromb Hemost</i> 2003;29(5):435–450
7	Senoo K, Lip GY. Comparative efficacy and safety of the non-vitamin k antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation. <i>Semin Thromb Hemost</i> 2015;41(2):146–153
8	Rodríguez de Córdoba S, Hidalgo MS, Pinto S, Tortajada A. Genetics of atypical hemolytic uremic syndrome (aHUS). <i>Semin Thromb Hemost</i> 2014;40(4):422–430
9	Boonyawat K, Crowther MA. Venous thromboembolism prophylaxis in critically ill patients. <i>Semin Thromb Hemost</i> 2015;41(1):68–74
10	Xiao X, Pickering MC, Smith RJ. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis. <i>Semin Thromb Hemost</i> . 2014;40(4):465–471
11	Levi M, Poll TV. Coagulation in patients with severe sepsis. <i>Semin Thromb Hemost</i> 2015;41(1):9–15
12	Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus NovoSeven in hemophilia patients with inhibitors. <i>Semin Thromb Hemost</i> 2013;39(7):772–778
13	Lippi G, Falavaro EJ, Mattiuzzi C. Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring? <i>Semin Thromb Hemost</i> 2014;40(7):756–765
14	Knöbl P. Inherited and acquired thrombotic thrombocytopenic purpura (TTP) in adults. <i>Semin Thromb Hemost</i> 2014;40(4):493–502
15	Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. <i>Semin Thromb Hemost</i> 2013;39(5):559–566

arrhythmias, hypertension and cardiovascular events, which may be further magnified by other potential effects such as increased respiratory and flow respiratory resistance. We are

**Fig. 2** Dr. Shannon Bates.

therefore really pleased that this article has generated such huge interest around this very actual public health issue."

From Dr. Philippe de Moerloose (→**Fig. 4**), "I am very honored to receive one of the 2016 Most Popular Article Awards for a review on Congenital Fibrinogen Disorders,

**Fig. 3** Dr. Giuseppe Lippi.



**Fig. 4** Dr. Philippe de Moerloose.

written with my co-authors and close colleagues Alessandro Casini and Marguerite Neerman-Arbez. In Geneva, we have been working for more than 15 years on the genetic basis and clinical consequences of fibrinogen deficiencies. The fundamental knowledge gained in this field during the past decade has been quite substantial and has translated into a better comprehension of our patient phenotypes with a more tailored approach to their treatment. We are very pleased to learn that a large number of STH readers appreciated our updated review.”

From Dr. Sanjeev Sethi (► **Fig. 5**), “It is indeed an honor to be selected for one of the 2016 Most Popular Article Awards. Understanding the pathology behind C3 glomerulopathy and atypical hemolytic uremic syndrome is the key to the correct diagnosis, evaluation, and management of these patients. Over the last few years great advances have been made in understanding the role of alternative pathway of complement in C3 glomerulopathy and atypical hemolytic uremic syndrome. With better elucidation of the pathophysiology, the



**Fig. 5** Dr. Sanjeev Sethi.

next step is the development of new agents that can target the specific underlying abnormality or defect that cause C3 glomerulopathy and atypical hemolytic uremic syndrome. I am very glad that our review of the pathology of these disease entities was well received, and I would also like to sincerely thank my colleague, friend and coauthor, Dr. Fernando Fer-venza, with whom I have had numerous great discussions and collaborations.”

I would like, as always, to thank not only all of the authors listed in the tables, but also the contributing authors who did not manage to make these listings, as well as all the guest editors of issues recently published in *Seminars in Thrombosis & Hemostasis*. Finally, as always, I look forward to seeing future listings!

## References

- 1 Favaloro EJ. Editorial. Welcome to a Special Issue of *Seminars in Thrombosis and Hemostasis*—The Closing Issue for 2008. *Semin Thromb Hemost* 2008;34:693–696
- 2 Favaloro EJ. A tribute to Eberhard F. Mammen, M.D. (1930–2008). *Semin Thromb Hemost* 2008;34(8):703–707
- 3 Favaloro EJ. Editorial. Welcome to the first issue of *Seminars in Thrombosis and Hemostasis* for 2009. *Semin Thromb Hemost* 2009;35:1–2
- 4 Favaloro EJ. Editorial. Winners of the Inaugural Eberhard F. Mammen Award for Most Popular Article. *Semin Thromb Hemost* 2009; 35:587–590
- 5 Favaloro EJ. Editorial. 2009 Eberhard F. Mammen Young Investigator Award Winners. *Semin Thromb Hemost* 2010; 36:469–470
- 6 Favaloro EJ. Winners of the 2010 Eberhard F. Mammen award for most popular article during 2008–2009. *Semin Thromb Hemost* 2010;36(7):685–692
- 7 Favaloro EJ. 2011 Eberhard F. Mammen award announcements. *Semin Thromb Hemost* 2011;37(5):431–439
- 8 Favaloro EJ. 2012 Eberhard F. Mammen award announcements. *Semin Thromb Hemost* 2012;38:425–432
- 9 Favaloro EJ. 2013 Eberhard F. Mammen award announcements. *Semin Thromb Hemost* 2013;39:567–574
- 10 Favaloro EJ. 2014 Eberhard F. Mammen award announcements: Part I - most popular articles. *Semin Thromb Hemost* 2014;40(4): 407–412
- 11 Favaloro EJ. 2014 Eberhard F. Mammen award announcements: part II-Young Investigator Awards. *Semin Thromb Hemost* 2014; 40(7):718–723
- 12 Favaloro EJ. 2015 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles. *Semin Thromb Hemost* 2015;41(7): 673–679
- 13 Favaloro EJ. 2015 Eberhard F. Mammen Award announcements: part II-Young Investigator Awards. *Semin Thromb Hemost* 2015; 41(8):809–815
- 14 Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. *Semin Thromb Hemost* 2012;38(7): 673–682
- 15 Lippi G, Favaloro EJ, Meschi T, Mattiuzzi C, Borghi L, Cervellin G. E-cigarettes and cardiovascular risk: beyond science and mysticism. *Semin Thromb Hemost* 2014;40(1):60–65
- 16 Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. *Semin Thromb Hemost* 2014;40(2):163–171
- 17 Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach. *Semin Thromb Hemost* 2014;40(1):106–114

- 18 Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated thrombosis. *Semin Thromb Hemost* 2014;40(3):277–283
- 19 Raskob GE, Angchaisuksiri P, Blanco AN, et al; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. *Semin Thromb Hemost* 2014;40(7):724–735
- 20 Favalaro EJ. Clinical utility of the PFA-100. *Semin Thromb Hemost* 2008;34(8):709–733
- 21 Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. *Semin Thromb Hemost* 2015;41(1):49–60
- 22 Zolfaghari S, Harenberg J, Froelich L, Wehling M, Weiss C. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy. *Semin Thromb Hemost* 2014;40(1):121–128
- 23 Althaus K, Greinacher A. MYH9-related platelet disorders. *Semin Thromb Hemost* 2009;35(2):189–203
- 24 Nurdan AT. Platelet membrane glycoproteins: a historical review. *Semin Thromb Hemost* 2014;40(5):577–584
- 25 Harenberg J, Kraemer S, Du S, et al. Determination of direct oral anticoagulants from human serum samples. *Semin Thromb Hemost* 2014;40(1):129–134
- 26 Favalaro EJ, Lippi G. Laboratory testing in the era of direct or non-vitamin K antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors. *Semin Thromb Hemost* 2015;41(2):208–227
- 27 Wada H, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. *Semin Thromb Hemost* 2008;34(8):772–778
- 28 Harenberg J, Du S, Krämer S, Weiss C, Krämer R, Wehling M. Patients' serum and urine as easily accessible samples for the measurement of non-vitamin K antagonist oral anticoagulants. *Semin Thromb Hemost* 2015;41(2):228–236
- 29 de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. *Semin Thromb Hemost* 2013;39(6):585–595
- 30 Sethi S, Fervenza FC. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS). *Semin Thromb Hemost* 2014;40(4):416–421
- 31 Riedl M, Fakhouri F, Le Quintrec M, et al. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. *Semin Thromb Hemost* 2014;40(4):444–464
- 32 Duga S, Salomon O. Congenital factor XI deficiency: an update. *Semin Thromb Hemost* 2013;39(6):621–631
- 33 Vivarelli M, Emma F. Treatment of C3 glomerulopathy with complement blockers. *Semin Thromb Hemost* 2014;40(4):472–477
- 34 Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. *Semin Thromb Hemost* 2003;29(5):435–450
- 35 Senoo K, Lip GY. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with non-valvular atrial fibrillation. *Semin Thromb Hemost* 2015;41(2):146–153
- 36 Rodríguez de Córdoba S, Hidalgo MS, Pinto S, Tortajada A. Genetics of atypical hemolytic uremic syndrome (aHUS). *Semin Thromb Hemost* 2014;40(4):422–430
- 37 Boonyawat K, Crowther MA. Venous thromboembolism prophylaxis in critically ill patients. *Semin Thromb Hemost* 2015;41(1):68–74
- 38 Xiao X, Pickering MC, Smith RJ. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis. *Semin Thromb Hemost* 2014;40(4):465–471
- 39 Levi M, Poll T. Coagulation in patients with severe sepsis. *Semin Thromb Hemost* 2015;41(1):9–15
- 40 Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus NovoSeven in hemophilia patients with inhibitors. *Semin Thromb Hemost* 2013;39(7):772–778
- 41 Lippi G, Favalaro EJ, Mattiuzzi C. Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring? *Semin Thromb Hemost* 2014;40(7):756–765
- 42 Knöbl P. Inherited and acquired thrombotic thrombocytopenic purpura (TTP) in adults. *Semin Thromb Hemost* 2014;40(4):493–502
- 43 Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. *Semin Thromb Hemost* 2013;39(5):559–566